Inhibitor kinazy Brutona u chorych z nawrotowym lub opornym na leczenie chloniakiem z komórek plaszcza - Wyniki miedzynarodowego, wieloosrodkowego, badania II fazy z ibrutynibem (PCI-32765) - EHA Encore

Translated title of the contribution: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma - Results of an international, multicenter, phase 2 study of Ibrutinib (PCI-32765) - EHA Encore
  • Wojciech Jurczak
  • , Simon Rule
  • , Peter Martin
  • , Rebecca Auer
  • , Brad S. Kahl
  • , Agnieszka Giza
  • , Bozena Jachimczak
  • , Ranjana H. Advani
  • , Jorge Romaguera
  • , Michael Williams
  • , Jacqueline Barrientos
  • , Ewa Chmielowska
  • , John Radford
  • , Stephan Stilgenbauer
  • , Jesse McGreivy
  • , Fong Clow
  • , Darrin M. Beaupre
  • , Lori Kunkel
  • , Andre Goy
  • , Kristie A. Blum
    • Wiktor Jedrzejczak, Michael L. Wang

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma - Results of an international, multicenter, phase 2 study of Ibrutinib (PCI-32765) - EHA Encore'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science